ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Thrombin-Antithrombin Complexes and sICAM-1 Are Associated With In-Hospital Mortality in COVID-19 Patients With Inflammatory Storm.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AimTo evaluate whether endothelial activation (soluble intercellular adhesion molecule-1, sICAM-1) and thrombotic activation (thrombin-antithrombin complexes, TAT) markers provide prognostic information beyond standard inflammatory markers for in-hospital mortality in COVID-19 patients with cytokine storm.Materials and methodsProspective cohort study of 47 patients with severe SARS-CoV-2 pneumonia admitted November 2020-February 2021 to District Hospital, Debica, Poland. Patients were stratified by cytokine storm profile (CRP >50 mg/L or IL-6 >30 pg/mL) and survival status. Blood biomarkers included CRP, IL-6, sICAM-1, TAT, d-dimer, and antiphospholipid antibodies.ResultsMortality rate was 40.4% (19/47 patients). Among patients with cytokine storm, TAT and sICAM-1 levels were significantly higher in non-survivors versus survivors (TAT: 15.4 (12.2-23.6) ng/mL vs. 11.6 (11.0-14.8) ng/mL, p=0.037; sICAM-1: 12.0 (5.6-35.3) ng/mL vs. 4.3 (2.5-23.9) ng/ml, p=0.033), whereas d-dimer and anticardiolipin IgM did not differentiate mortality outcomes. Elevated TAT was detected in 100% of patients, d-dimer in 93.6%, anticardiolipin IgM in 40.4%, and sICAM-1 in 21.3%. In the multivariable exploratory model based on Firth's logistic regression, TAT ≥12.14 ng/mL and sICAM-1 ≥4.0 ng/mL emerged as potential independent predictors of mortality (OR: 6.27, 95% CI: 1.31-29.99 and OR: 8.68, 95% CI: 1.22-62.15, respectively). Traditional prognostic factors (diabetes on insulin, and blood desaturation) also discriminated poor outcomes.ConclusionssICAM-1 and TAT were associated with in-hospital mortality within the high-risk subgroup of COVID-19 patients with cytokine storm, suggesting prognostic information beyond conventional inflammatory markers and d-dimer. Given the limited sample size, these exploratory findings should be regarded as hypothesis-generating and require validation in larger, multicentre cohorts before informing risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.